Cleerly Inc.
1099 18th Street, Suite 2860
Denver , Colorado 80202
United States
[email protected]
Visit Website
Product Categories:
SPECT Imaging, Computed Tomography (CT), Information Technology, Artificial Intelligence

Related Content

Company’s AI-enabled technology for future heart attack risk assessment accepted into FDA’s TAP Pilot and to be validated in landmark TRANSFORM trial
News | FDA
Cleerly Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System

March 6, 2024 — Cleerly, the company on a mission to create a new standard of care to aid in the diagnosis of heart ...

Home March 06, 2024
arrow
FDA-cleared Cleerly ISCHEMIA will assist healthcare professionals in clinical diagnosis and decision making for coronary artery disease
News | Artificial Intelligence
Cleerly ISCHEMIA Software Device Billable With AMA Category I CPT Code for Noninvasive Estimates of Fractional Flow Reserve

February 23, 2024 — Cleerly, the company creating a new standard of care to aid in the diagnosis of heart disease ...

Home February 23, 2024
arrow
Cleerly has announced continued strong scientific evidence supporting the clinical utility of its products, detailing a study published online on Jan. 25, 2024 in the European Heart Journal Cardiovascular Imaging
News | Artificial Intelligence
Results of CERTAIN Study Demonstrate Prominent Effects of Cleerly Products on Changing Clinical Management for Patients Suspected of Coronary Artery Disease

February 13, 2024 — Cleerly, a digital healthcare company focused on artificial intelligence (AI)-driven heart disease ...

Home February 13, 2024
arrow
FDA cleared, evidence-based AI and machine learning-based algorithm detects heart disease-associated ischemia
News | Artificial Intelligence
Cleerly Launches Cleerly ISCHEMIA Solution for Heart Disease Analysis

January 9, 2024 — Cleerly, the company working to create a new standard of care for the diagnosis of heart disease ...

Home January 09, 2024
arrow
As coronary computed tomography angiography (CCTA) progresses towards becoming the primary imaging modality for not only diagnostic purposes, but also for clinical trial endpoints, there is a need to address the requirements for generating high-quality CCTA image data to ensure accurate and robust CAD assessments
Feature | Computed Tomography (CT)| By Andrew Michalski, PhD and Rohit Sood MD, PhD
From the Clinic to Pharmaceutical Clinical Trials: Considerations for using Coronary CT Angiography (CCTA) in Atherosclerotic Cardiovascular Disease (ASCVD) Clinical Trials

Coronary artery disease (CAD), also known as ischemic heart disease, is the most common heart disease with a prevalence ...

Home December 05, 2023
arrow
Data from the randomized control trial will advance evidence for evaluation and treatment of heart disease by studying actual disease: atherosclerosis.
News | AHA
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association AHA 2023 Scientific Sessions

November 11, 2023 — An announcement on partners to collaborate in the TRANSFORM trial was made today during the American ...

Home November 11, 2023
arrow
News | Artificial Intelligence
AI Breakthrough Award Presented to Cleerly CCTA Digital Care Platform

August 10, 2023 — Cleerly, an artificial intelligence (AI) digital healthcare company, recently announced it was named ...

Home August 10, 2023
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now